These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 31644396)

  • 1. Challenges and solutions in the development of vaccines against emerging and neglected infectious diseases.
    Maslow JN
    Hum Vaccin Immunother; 2019; 15(10):2230-2234. PubMed ID: 31644396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are we prepared for emerging flaviviruses in Europe? Challenges for vaccination.
    Kaaijk P; Luytjes W
    Hum Vaccin Immunother; 2018 Feb; 14(2):337-344. PubMed ID: 29053401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging infectious diseases: A proactive approach.
    Bloom DE; Black S; Rappuoli R
    Proc Natl Acad Sci U S A; 2017 Apr; 114(16):4055-4059. PubMed ID: 28396438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging vector-borne flavivirus diseases: are vaccines the solution?
    Gubler DJ
    Expert Rev Vaccines; 2011 May; 10(5):563-5. PubMed ID: 21604976
    [No Abstract]   [Full Text] [Related]  

  • 5. Vaccines for emerging infectious diseases: Lessons from MERS coronavirus and Zika virus.
    Maslow JN
    Hum Vaccin Immunother; 2017 Dec; 13(12):2918-2930. PubMed ID: 28846484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccines for neglected, emerging and re-emerging diseases.
    Madhav A; Mehrotra T; Sinha P; Mutreja A
    Semin Immunol; 2020 Aug; 50():101423. PubMed ID: 33250352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine development: Current trends and technologies.
    Poria R; Kala D; Nagraik R; Dhir Y; Dhir S; Singh B; Kaushik NK; Noorani MS; Kaushal A; Gupta S
    Life Sci; 2024 Jan; 336():122331. PubMed ID: 38070863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing vaccines against flavivirus diseases: past success, present hopes and future challenges.
    Stephenson JR
    Novartis Found Symp; 2006; 277():193-201; discussion 201-5, 251-3. PubMed ID: 17319163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virus like particle-based vaccines against emerging infectious disease viruses.
    Liu J; Dai S; Wang M; Hu Z; Wang H; Deng F
    Virol Sin; 2016 Aug; 31(4):279-87. PubMed ID: 27405928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Funding vaccines for emerging infectious diseases.
    Wong G; Qiu X
    Hum Vaccin Immunother; 2018 Jul; 14(7):1760-1762. PubMed ID: 29194012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping time use in clinical trials for vaccines against emerging infectious diseases.
    Mandi H; Yimer SA; Norheim G
    Clin Trials; 2021 Jun; 18(3):286-294. PubMed ID: 33653146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mRNA Vaccine Development for Emerging Animal and Zoonotic Diseases.
    Le T; Sun C; Chang J; Zhang G; Yin X
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid response to an emerging infectious disease - Lessons learned from development of a synthetic DNA vaccine targeting Zika virus.
    Kudchodkar SB; Choi H; Reuschel EL; Esquivel R; Jin-Ah Kwon J; Jeong M; Maslow JN; Reed CC; White S; Kim JJ; Kobinger GP; Tebas P; Weiner DB; Muthumani K
    Microbes Infect; 2018 Dec; 20(11-12):676-684. PubMed ID: 29555345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges of evaluating and modelling vaccination in emerging infectious diseases.
    Madewell ZJ; Dean NE; Berlin JA; Coplan PM; Davis KJ; Struchiner CJ; Halloran ME
    Epidemics; 2021 Dec; 37():100506. PubMed ID: 34628108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccinomics: a future avenue for vaccine development against emerging pathogens.
    de la Fuente J; Contreras M
    Expert Rev Vaccines; 2021 Dec; 20(12):1561-1569. PubMed ID: 34582295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine development for emerging infectious diseases.
    Excler JL; Saville M; Berkley S; Kim JH
    Nat Med; 2021 Apr; 27(4):591-600. PubMed ID: 33846611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccines for emerging pathogens: from research to the clinic. Part two.
    Williamson ED
    Clin Exp Immunol; 2019 Nov; 198(2):141-142. PubMed ID: 31625155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The need and challenges for development of vaccines against emerging infectious diseases.
    Clemens SAC; Clemens R
    J Pediatr (Rio J); 2023; 99 Suppl 1(Suppl 1):S37-S45. PubMed ID: 36495947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meeting report: CEPI consultation on accelerating access to novel vaccines against emerging infectious diseases for pregnant and lactating women, London, 12-13 February 2020.
    Voss G; Jacquet JM; Tornieporth N; Kampmann B; Karron R; Meulen AS; Chen R; Gruber M; Lurie N; Weller C; Cramer JP; Saville M; Darko M
    Vaccine; 2021 Dec; 39(51):7357-7362. PubMed ID: 34799142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Letter from the Editor.
    Hum Vaccin Immunother; 2019; 15(10):2227. PubMed ID: 31644394
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.